Articles tagged with Leukemia
A research group in Japan and Korea found that certain dipeptide species support CML stem cell activity. Pharmacological inhibition of nutrient uptake decreased CML stem cell activity in vivo, suggesting a potential therapeutic target for CML therapy. This discovery may provide concrete benefits to patients with CML.
A team of international scientists decoded the molecular characteristics of a fatal subtype of leukemia in children, paving the way for new therapeutic approaches. The study identified genetic aberrations and altered gene expression programs that lead to tumorigenesis, providing potential druggable targets.
Scientists have decoded the genome and transcriptome of an incurable subtype of acute lymphoblastic leukemia, revealing a novel program associated with leukemic cells. The study identifies key genes that trigger a reprogramming of the leukemia cells, leading to promising drug tests, including Venetoclax.
A Dartmouth team has successfully synthesized molecules that induce rapid apoptosis in leukemia cells, paving the way for further study of their biological mechanism of action. The findings hold promise for developing novel therapeutic strategies against cancer and other diseases linked to abnormal cell death.
The Damon Runyon Cancer Research Foundation has established a new award to increase the number of physician-scientists in cancer research. The grant provides $100,000 per year for three years and up to $100,000 of medical school debt repayment. Two awardees will investigate novel approaches to fighting cancer.
A small pilot study found an experimental treatment approach can send deadly leukemia into remission in patients who have failed standard therapy. The combination of immunotherapy and gene manipulation buys critical time for patients to receive a potentially life-saving stem cell transplant.
Research suggests that breastfeeding for at least six months can significantly reduce the risk of childhood leukemia. The study analyzed data from 18 studies and found a 19% lower risk compared to no breastfeeding or shorter breastfeeding periods. Breast milk's immunological components may play a key role in this association.
A UCSF-led team discovered that the Haemophilus influenzae Type b vaccine protects against acute lymphoblastic leukemia by preventing the conversion of 'pre-leukemia' blood cells into full-blown cancer. Chronic infections push these cells into malignancy.
Researchers at Children's Hospital Los Angeles found that minimal residual disease alone is not predictive of risk or outcome in children with T-cell leukemia. Despite having few remaining leukemia cells, patients achieved complete remission and had excellent outcomes without intensifying therapy.
A new gene involved in blood-forming stem cells has been discovered by U-M researchers, providing insights into the body's ability to create and maintain a healthy blood supply. The Ash1l gene plays a critical role in regulating hematopoietic stem cell maintenance and self-renewal potential.
Dr. Owen Witte, a pioneer in human leukemias and immune disorders, received the AACR G.H.A. Clowes Memorial Award for his groundbreaking work on tyrosine kinases as drug targets. His discoveries have led to multiple approved targeted therapies, transforming patient outcomes.
Researchers at Michigan Medicine have developed a new compound that shows promise in treating acute leukemia and may also play a role in prostate cancer. The MLL-menin interaction is a key driver of the disease, and blocking this interaction has shown potential in laboratory studies.
Researchers identified a panel of genetic markers that predicted which tumor samples would likely respond to treatment for chronic myelomonocytic leukemia, a cancer affecting older adults with limited treatment options.
Researchers at the University of Michigan Medical School found that patients with chronic myelomonocytic leukemia (CMML) who responded to decitabine treatment had a distinct DNA methylation pattern. This signature can be used to predict patient response to treatment, enabling more effective treatment planning.
A new engineered protein-based medicine has been shown to overcome radiation resistance in leukemia by selectively binding to leukemia cells and amplifying the potency of radiation therapy. In mouse models, this precision medicine improved survival rates in aggressive human leukemia with minimal side effects.
A University of Colorado Cancer Center study found a heritable genetic cause of acute lymphoblastic leukemia (ALL), similar to the BRCA mutation that affects breast and ovarian cancer risk. The ETV6 gene mutation is present at birth and increases the development of ALL, with the potential for future strategies to prevent the disease.
A study by St. Jude Children's Research Hospital found that measuring residual leukemia cells in patient bone marrow during early weeks of chemotherapy helps identify high-risk patients who need intensive therapy. The technique improved survival rates for young leukemia patients, with 93.5% alive five years after diagnosis.
Researchers at Stanford University School of Medicine have discovered a method to transform human leukemia cells into harmless immune cells called macrophages. This breakthrough offers potential hope for treating aggressive cancers like B-cell acute lymphoblastic leukemia.
Researchers found that infants with a rare form of leukemia have surprisingly few genetic alterations beyond the MLL gene chromosomal rearrangement, suggesting targeting this abnormal protein may improve survival rates. The study also highlights the need for personalized treatments in pediatric cancer.
A study of 308 patients with CLL found that 10% discontinued ibrutinib therapy due to disease progression and Richter's transformation, while others stopped for other reasons. Patients who discontinued therapy had poor prognosis, highlighting the need for new research targets.
A study found that a gene variant is associated with a higher incidence and severity of peripheral neuropathy in children treated with vincristine, a widely used anticancer agent. The variant, CEP72, was linked to an increased risk of nerve damage and pain in patients receiving vincristine treatment.
A study published in Nature identified axitinib as a promising drug candidate for treating drug-resistant leukemia. The researchers used a novel screening method and partnered with Pfizer to define the mechanism of action, providing new insights into blocking cancer-causing kinases.
Researchers found that non-mutated CLL shows increased gene expression variability, while mutated leukaemia has lower variability. This variation is linked to tumour aggressiveness and may help predict disease subtype.
Researchers at the University of Veterinary Medicine, Vienna, have found that CDK6 is essential for activating leukemic stem cells, which causes leukemia. Inhibiting CDK6 may prevent relapse, while leaving healthy stem cells unaffected.
A new protein-based therapy has been developed to target drug-resistant leukemia cells, with promising results in mouse models and potentially amplifying the potency of standard treatment options. The fusion protein CD19L-sTRAIL selectively binds and delivers a 'death signal' to leukemia cells.
Enzymes linked to diabetes and obesity play key roles in arthritis and leukemia, potentially opening new avenues for treating these diseases. Targeting ether lipids may reduce neutrophil levels, allowing the immune system to return to normal.
Researchers discovered that crosstalk between leukemia cells and stromal cells in the spleen is crucial for cancer growth. Blocking chemokine receptor CXCR5 prevents cancer cell entry and proliferation, identifying new targets for future therapies.
Researchers from Frankfurt and Moscow develop kinase inhibitor PF-114 effective against Philadelphia chromosome-positive leukemia, including resistant cases. The new substance offers a more favorable profile than existing Ponatinib, paving the way for further clinical trials.
Researchers at the University of Southern California have engineered a new approach to attack childhood leukemia, a devastating form of cancer. They've designed a synthetic gene therapy that can selectively target and kill cancer stem cells, offering hope for children with relapsed disease.
Researchers discovered a new correlation between specific molecular features and CLL subgroups with different prognosis. The study identified subsets of patients with distinct clinical courses, allowing for better adjustment of therapeutic strategies and follow-up.
Research at Children's Hospital Los Angeles found that obese patients with acute lymphoblastic leukemia are more than twice as likely to have minimal residual disease, a strong predictor of long-term survival and disease recurrence. The study suggests modifying chemotherapy regimens for obese patients may improve outcomes.
Researchers at NYU Langone Health have made breakthroughs in treating T-cell acute lymphoblastic leukemia by blocking the action of an enzyme called JMJD3. The treatment, GSKJ4, has shown promising results in mice and human lab cells, with cancer cells dying when treated with the experimental drug.
A study by Harvard University scientists has identified a non-toxic way to target leukemia cells' metabolism without harming normal cells. This breakthrough could lead to new treatments for leukemia patients.
Researchers at Children's Hospital Los Angeles have developed a method to multiply natural killer cells from patients with leukemia in the lab. These autologous NK cells can be used to destroy cancer cells, potentially providing a less toxic and more effective treatment for pediatric leukemia.
Researchers at NYU Langone Medical Center identified a possible new drug target, LUNAR1, for treating childhood blood cancer. Blocking LUNAR1's action stalled leukemia progression and may offer an alternative to standard chemotherapy.
Scott Armstrong, M.D., Ph.D., has made significant contributions to the field of hematology with his research on leukemia and cancer stem cell biology. His work has led to new therapies for patients diagnosed with devastating leukemias, according to the American Society of Hematology.
A new study by Prof. Gennaro De Libero and his team at the University of Basel identifies a lipid molecule, methyl-lysophosphatidic acid (mLPA), that stimulates specific T cells to kill leukemia cells. This breakthrough discovery offers new avenues for non-invasive cancer immunotherapies.
Researchers have found a unique genetic pattern in leukemia cells of 22 patients diagnosed with cytogenetically normal acute myelogenous leukemia, which may lead to more targeted therapy and definitive prognosis.
A recent German study on a new drug therapy for chronic lymphocytic leukemia (CLL) has been published in the New England Journal of Medicine. North Shore-LIJ Cancer Institute doctors highlight that most CLL patients are elderly with coexisting health issues, and the study found that subjects receiving obinutuzumab-chlorambucil had an a...
Researchers found that a common mutation activates the Akt pathway, rendering cells resistant to chemotherapy and increasing growth. Inhibition of this pathway restored leukemic cell responses to front-line therapy.
A UCLA research team has developed a treatment that blocks two metabolic pathways needed by leukemia cells, halting their growth and leading to cell death. The experimental treatment showed promising results in mice with acute lymphoblastic leukemia.
Researchers develop novel two-pronged strategy targeting DNA synthesis to treat leukemia in mice. The approach, which involves blocking both the de novo and salvage pathways, shows promise as a targeted metabolic intervention for acute lymphoblastic leukemia.
A new study reveals that babies who develop leukemia during the first year of life inherit a strong genetic predisposition to the disease. The research found that infants with leukemia have an excess of damaging changes in genes linked to leukemia, which can be passed from both parents.
A team of researchers at the University of Montreal has discovered a promising new approach to treating leukemia by targeting the Brg1 gene. The study found that removing or inhibiting this gene can permanently shut down cancerous cell growth and division.
Researchers aim to make blood cancers more vulnerable to treatment by targeting the hiding spots where leukemia cells reside. Initial focus is on blood vessels, which provide a safe haven for these cells.
Researchers have created an artificial bone marrow that can reproduce hematopoietic stem cells, which could facilitate the treatment of leukemia. The new technology uses synthetic polymers and protein building blocks to mimic the natural environment of bone marrow, allowing for more efficient stem cell reproduction.
Researchers identify two therapeutic targets to block cancer cell growth: PAK and STAT5. The shutdown of either target significantly delays leukemia progression in mice, offering new hope for cancer treatment.
Researchers have developed genetically engineered cell therapies demonstrating early efficacy and safety in patients with blood disorders. The treatments use a patient's own re-engineered cells to attack their disease, offering an innovative approach to precision medicine.
Researchers found that LIF levels are predictive of NPC patient response to radiation therapy, with patients resistant to treatment having higher serum levels of the cytokine. LIF promotes NPC progression and radioresistance.
Researchers have found a rare case where a bone marrow transplant cured a child's peanut allergy. The study suggests genetic modification during immune cell development may play a role in causing allergies.
A recent EORTC trial found that detecting ERG gene deletion at diagnosis of childhood B-cell precursor acute lymphoblastic leukemia (ALL) is beneficial for risk stratification. Patients with the ERG gene deletion had an 8-year event-free survival rate of 86.4% and overall survival of 95.6%.
Researchers at UAlberta have discovered a potential new treatment for colitis by using a leukemia drug to reverse symptoms in lab tests. The discovery suggests that inhibiting inflammation can reduce the likelihood of patients with ulcerative colitis developing colorectal cancer later in life.
Thomas Kipps, MD, PhD, receives a 5-year, $6.25 million grant from The Leukemia & Lymphoma Society to support research on chronic lymphocytic leukemia (CLL). The grant aims to identify potential new therapies that target identified pathways supporting leukemia-cell survival.
Researchers identified a gene mutation that predisposes children to the most common form of childhood leukemia. The PAX5 mutation was found in multiple generations of two families, leading to a marked reduction of normal PAX5 activity in leukemia cells.
Researchers uncover how ABL regulatory unit controls cell fate in CML, with implications for cancer treatment. The study finds that anchoring ABL on the cell membrane is essential for apoptosis, highlighting a potential target for novel therapies.
Researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice. These non-replicating particles, derived from rhabdovirus, work by direct cytolysis and induction of antitumor immunity, showing promise as a new therapy for leukemia.
A study suggests blocking part of a DNA repair complex can increase chemotherapy effectiveness and enhance survival in therapy-resistant leukemia. Researchers found that combining mTOR inhibitors with chemotherapy was far more effective at treating T-cell acute lymphoblastic leukemia (T-ALL) than standalone treatments.
A new vaccine has shown promise in boosting the immune system's ability to attack leukemia cells in post-transplant patients. The personalized tumor vaccine, which includes the patient's own irradiated leukemia cells combined with an immune stimulant, has been shown to induce a strong and selective immune response.
Researchers discovered a mutated protein that selectively enhances cancer cells while sparing healthy ones. The findings suggest a potent new therapeutic target for certain types of leukemia.
Researchers at Scripps Research Institute receive $1.4 million from the National Cancer Institute to create a potential new drug targeting malignant cells in CLL, while sparing normal tissues. The study aims to deliver cytotoxic drugs with specific targeting using cell surface receptor TOSO and receptor tyrosine kinase ROR1.